Gain Therapeutics, Inc. (GANX) · 10+ Years of Financial statements

Income Statement	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Sales/Revenue/Turnover	- -	- -	- -	- -	- -	- -
+ Sales & Services Revenue	- -	- -	- -	- -	- -	- -
- Cost of Revenue	- -	- -	- -	- -	- -	- -
+ Cost of Goods & Services	- -	- -	- -	- -	- -	- -
Gross Profit	- -	- -	- -	- -	- -	- -
+ Other Operating Income	- -	- -	- -	- -	- -	- -
- Operating Expenses	1	2	4	14	18	22
+ Selling, General & Admin	- -	1	1	7	10	11
+ Research & Development	1	2	2	7	8	12
+ Other Operating Expense	- -	- -	- -	- -	- -	- -
Operating Income (Loss)	-1	-2	-3	-14	-18	-22
- Non-Operating (Income) Loss	- -	- -	- -	- -	- -	- -
+ Interest Expense, Net	- -	- -	- -	- -	- -	- -
+ Interest Expense	- -	- -	- -	- -	- -	- -
- Interest Income	- -	- -	- -	- -	- -	- -
+ Other Non-Op (Income) Loss	- -	- -	- -	- -	- -	- -
Pretax Income	-1	-2	-4	-14	-17	-22
- Income Tax Expense (Benefit)	- -	- -	- -	- -	- -	- -
- (Income) Loss from Affiliates	- -	- -	- -	- -	- -	- -
Income (Loss) from Cont Ops	-1	-2	-4	-14	-18	-22
- Net Extraordinary Losses (Gains)	- -	- -	- -	- -	- -	- -
+ Discontinued Operations	- -	- -	- -	- -	- -	- -
+ Extraord. & Accounting Changes	- -	- -	- -	- -	- -	- -
Income (Loss) Incl. MI	-1	-2	-4	-14	-18	-22
- Minority Interest	- -	- -	- -	- -	- -	- -
Net Income, GAAP	-1	-2	-4	-14	-18	-22
- Preferred Dividends	- -	- -	- -	- -	- -	- -
- Other Adjustments	- -	- -	- -	- -	- -	- -
Net Income Avail to Common, GAAP	-1	-2	-4	-14	-18	-22
Basic Weighted Avg Shares	6	6	3	10	12	13
Basic EPS, GAAP	-0.19	-0.37	-1.33	-1.37	-1.48	-1.71
Basic EPS from Cont Ops	-0.19	-0.37	-1.33	-1.37	-1.48	-1.71
Diluted Weighted Avg Shares	6	6	3	10	12	13
Diluted EPS, GAAP	-0.19	-0.37	-1.33	-1.37	-1.48	-1.71
Diluted EPS from Cont Ops	-0.19	-0.37	-1.33	-1.37	-1.48	-1.71
EBITDA	-1	-2	-3	-14	-18	-22
EBITDA Margin (%)	-4,986.06	-5,078.66	-12,014.32	-8,370.42	-12,642.3	-40,176.79
EBITA	-1	-2	-3	-14	-18	-22
EBIT	-1	-2	-3	-14	-18	-22
Gross Margin (%)	100	100	100	100	100	100
Operating Margin (%)	-4,989.66	-5,084.89	-12,047.54	-8,379.8	-12,688.1	-40,328.26
Profit Margin (%)	-5,364.36	-5,310.88	-12,387.67	-8,418.86	-12,555.13	-40,354.33
Sales per Employee	- -	- -	2,063	5,689	4,520	1,724
Dividend per Share	- -	- -	- -	- -	- -	- -
Depreciation Expense	- -	- -	- -	- -	- -	- -

Balance Sheet	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
Total Current Assets	- -	- -	9	38	21	18
+ Cash, Cash Equivalents & STI	- -	- -	7	37	20	17
+ Cash & Cash Equivalents	- -	- -	7	37	7	12
+ ST Investments	- -	- -	- -	- -	13	5
+ Accounts & Notes Receiv	- -	- -	- -	- -	- -	- -
+ Accounts Receivable, Net	- -	- -	- -	- -	- -	- -
+ Notes Receivable, Net	- -	- -	- -	- -	- -	- -
+ Loans Receivable, Net	- -	- -	- -	- -	- -	- -
+ Other Receivable, Net	- -	- -	- -	- -	- -	- -
+ Inventories	- -	- -	- -	- -	- -	- -
+ Raw Materials	- -	- -	- -	- -	- -	- -
+ Work In Process	- -	- -	- -	- -	- -	- -
+ Finished Goods	- -	- -	- -	- -	- -	- -
+ Inventory Adjustments	- -	- -	- -	- -	- -	- -
+ Other Inventory	- -	- -	- -	- -	- -	- -
+ Other ST Assets	- -	- -	1	1	1	1
+ Prepaid Expenses	- -	- -	- -	- -	- -	- -
+ ST Derivative & Hedging Assets	- -	- -	- -	- -	- -	- -
+ ST Assets Held-for-Sale	- -	- -	- -	- -	- -	- -
+ ST Deferred Tax Assets	- -	- -	- -	- -	- -	- -
+ Misc ST Assets	- -	- -	- -	- -	- -	- -
Total Noncurrent Assets	- -	- -	1	1	3	1
+ Property, Plant & Equip, Net	- -	- -	1	1	1	1
+ Property, Plant & Equip	- -	- -	1	1	1	1
- Accumulated Depreciation	- -	- -	- -	- -	- -	- -
+ LT Investments & Receivables	- -	- -	- -	- -	2	- -
+ LT Investments	- -	- -	- -	- -	2	- -
+ LT Receivables	- -	- -	- -	- -	- -	- -
+ Other LT Assets	- -	- -	- -	- -	- -	- -
+ Total Intangible Assets	- -	- -	- -	- -	- -	- -
+ Goodwill	- -	- -	- -	- -	- -	- -
+ Other Intangible Assets	- -	- -	- -	- -	- -	- -
+ LT Deferred Tax Assets	- -	- -	- -	- -	- -	- -
+ LT Derivative & Hedging Assets	- -	- -	- -	- -	- -	- -
+ Misc LT Assets	- -	- -	- -	- -	- -	- -
Total Assets	- -	1	10	39	24	19
+ Payables & Accruals	- -	- -	2	2	4	3
+ Accounts Payable	- -	- -	1	1	2	1
+ Accrued Taxes	- -	- -	- -	- -	- -	- -
+ Interest & Dividends Payable	- -	- -	- -	- -	- -	- -
+ Other Payables & Accruals	- -	- -	1	1	2	2
+ ST Debt	- -	- -	- -	- -	- -	- -
+ ST Borrowings	- -	- -	- -	- -	- -	- -
+ ST Finance Leases	- -	- -	- -	- -	- -	- -
+ Other ST Liabilities	- -	- -	- -	- -	- -	1
+ Deferred Revenue	- -	- -	- -	- -	- -	1
+ Derivatives & Hedging	- -	- -	- -	- -	- -	- -
+ Deferred Tax Liabilities	- -	- -	- -	- -	- -	- -
+ Misc ST Liabilities	- -	- -	- -	- -	- -	- -
Total Current Liabilities	- -	1	2	3	4	5
+ LT Debt	- -	- -	1	1	1	1
+ LT Borrowings	- -	- -	1	1	- -	- -
+ LT Finance Leases	- -	- -	- -	1	- -	- -
+ Other LT Liabilities	- -	- -	- -	- -	- -	- -
+ Accrued Liabilities	- -	- -	- -	- -	- -	- -
+ Pension Liabilities	- -	- -	- -	- -	- -	- -
+ Deferred Revenue	- -	- -	- -	- -	- -	- -
+ Deferred Tax Liabilities	- -	- -	- -	- -	- -	- -
+ Derivatives & Hedging	- -	- -	- -	- -	- -	- -
+ Misc LT Liabilities	- -	- -	- -	- -	- -	- -
Total Noncurrent Liabilities	- -	- -	1	2	1	1
Total Liabilities	- -	1	3	4	5	6
+ Preferred Equity and Hybrid Capital	- -	- -	- -	- -	- -	- -
+ Share Capital & APIC	- -	3	13	56	57	73
+ Common Stock	- -	- -	- -	- -	- -	- -
+ Additional Paid in Capital	- -	3	13	56	57	73
- Treasury Stock	- -	- -	- -	- -	- -	- -
+ Retained Earnings	- -	-3	-7	-21	-39	-61
+ Other Equity	- -	- -	- -	- -	- -	- -
Equity Before Minority Interest	- -	- -	6	35	19	13
+ Minority/Non Controlling Interest	- -	- -	- -	- -	- -	- -
Total Equity	- -	- -	6	35	19	13
Total Liabilities & Equity	- -	1	10	39	24	19
Shares Outstanding	6	6	11	12	12	16
Capital Leases - Total	- -	- -	1	1	1	- -
Net Debt	- -	- -	-7	-36	-7	-11
Net Debt to Equity	- -	67.43	-108.91	-103.93	-35.53	-89.26
Tangible Common Equity Ratio	- -	-68.15	64.57	89.25	78.15	67.25
Current Ratio	- -	0.49	4.25	14.78	5.11	3.59
Cash Conversion Cycle	- -	- -	- -	- -	- -	- -
Number of Employees	- -	- -	14	29	31	32

Cash Flow Statement	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y
+ Net Income	-1	-2	-4	-14	-18	-22
+ Depreciation & Amortization	- -	- -	- -	- -	- -	- -
+ Non-Cash Items	- -	- -	- -	2	1	3
+ Stock-Based Compensation	- -	- -	- -	1	2	3
+ Deferred Income Taxes	- -	- -	- -	- -	- -	- -
+ Asset Impairment Charge	- -	- -	- -	- -	- -	- -
+ Other Non-Cash Adj	- -	- -	- -	1	- -	- -
+ Chg in Non-Cash Work Cap	- -	- -	- -	- -	2	- -
+ (Inc) Dec in Accts Receiv	- -	- -	- -	- -	- -	- -
+ (Inc) Dec in Inventories	- -	- -	- -	- -	- -	- -
+ (Inc) Dec in Prepaid Assets	- -	- -	- -	-1	- -	- -
+ Inc (Dec) in Accts Payable	- -	- -	- -	-1	1	-1
+ Inc (Dec) in Other	- -	- -	- -	1	1	1
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -	- -
Cash from Operating Activities	-1	-2	-3	-12	-15	-19
+ Change in Fixed & Intang	- -	- -	- -	- -	- -	- -
+ Disp in Fixed & Intang	- -	- -	- -	- -	- -	- -
+ Disp of Fixed Prod Assets	- -	- -	- -	- -	- -	- -
+ Disp of Intangible Assets	- -	- -	- -	- -	- -	- -
+ Acq of Fixed & Intang	- -	- -	- -	- -	- -	- -
+ Acq of Fixed Prod Assets	- -	- -	- -	- -	- -	- -
+ Acq of Intangible Assets	- -	- -	- -	- -	- -	- -
+ Net Change in LT Investment	- -	- -	- -	- -	-15	10
+ Dec in LT Investment	- -	- -	- -	- -	3	12
+ Inc in LT Investment	- -	- -	- -	- -	-18	-2
+ Net Cash From Acq & Div	- -	- -	- -	- -	- -	- -
+ Cash from Divestitures	- -	- -	- -	- -	- -	- -
+ Cash for Acq of Subs	- -	- -	- -	- -	- -	- -
+ Cash for JVs	- -	- -	- -	- -	- -	- -
+ Other Investing Activities	- -	- -	- -	- -	- -	- -
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -	- -
Cash from Investing Activities	- -	- -	- -	- -	-15	10
+ Dividends Paid	- -	- -	- -	- -	- -	- -
+ Net Cash From Debt	1	- -	1	- -	- -	- -
+ Cash From Debt	1	- -	1	- -	- -	- -
+ Repayments of Debt	- -	- -	- -	- -	- -	- -
+ Cash (Repurchase) of Equity	- -	- -	- -	43	- -	13
+ Increase in Capital Stock	- -	- -	- -	43	- -	13
+ Decrease in Capital Stock	- -	- -	- -	- -	- -	- -
+ Other Financing Activities	- -	2	10	-1	- -	- -
+ Net Cash From Disc Ops	- -	- -	- -	- -	- -	- -
Cash from Financing Activities	1	2	10	42	- -	13
Effect of Foreign Exchange Rates	- -	- -	- -	- -	- -	- -
Net Changes in Cash	- -	- -	7	29	-30	4
Capital Expenditures	- -	- -	- -	- -	- -	- -
EBITDA	-1	-2	-3	-14	-18	-22
EBITDA Margin (%)	-4,986.06	-5,078.66	-12,014.32	-8,370.42	-12,642.3	-40,176.79
Net Cash Paid for Acquisitions	- -	- -	- -	- -	- -	- -
Free Cash Flow	-1	-2	-3	-12	-15	-19
Free Cash Flow to Firm	- -	- -	- -	- -	- -	- -
Free Cash Flow to Equity	- -	-2	-3	-12	-15	-19
Free Cash Flow per Basic Share	-0.13	-0.32	-1.22	-1.23	-1.25	-1.45
Price/Free Cash Flow	- -	- -	- -	-4.4	-2.44	-2.05
Cash Flow to Net Income	0.67	0.85	0.91	0.89	0.84	0.85

Gain Therapeutics, Inc.

GANX US

1.32

1.32